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Abstract
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The F508del and G542X are the
most common mutations found in US patients, accounting for 86.4% and 4.6%
of all mutations, respectively. The F508del causes deletion of the phenylalanine
residue at position 508 and is associated with impaired CFTR protein folding. The
G542X is a nonsense mutation that introduces a stop codon into the mRNA, thus
preventing normal CFTR protein synthesis. Here, we describe the generation of
CFTRF508del/F508del and CFTRG542X/G542X lambs using CRISPR/Cas9 and somatic
cell nuclear transfer (SCNT). First, we introduced either F508del or G542X mutations into sheep fetal fibroblasts that were subsequently used as nuclear donors
for SCNT. The newborn CF lambs develop pathology similar to CFTR−/− sheep
and CF patients. Moreover, tracheal epithelial cells from the CFTRF508del/F508del
lambs responded to a human CFTR (hCFTR) potentiator and correctors, and
those from CFTRG542X/G542X lambs showed modest restoration of CFTR function
following inhibition of nonsense-mediated decay (NMD) and aminoglycoside
antibiotic treatments. Thus, the phenotype and electrophysiology of these novel
models represent an important advance for testing new CF therapeutics and gene
therapy to improve the health of patients with this life-limiting disorder.
KEYWORDS
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I N T RO DU CT ION

Cystic Fibrosis (CF) is an autosomal recessive genetic disease that affects over 30,000 people in the United States

and results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that
disrupt the CFTR synthesis, folding, or function. The
CFTR protein is a well-
characterized cAMP-
regulated
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ATP-binding cassette (ABC) transporter responsible for
regulating anion transport, primarily chloride ions.1 The
CFTR protein is expressed in epithelial cells of multiple
organs such as the airways, pancreas, intestine, gallbladder, and male genital ducts. Important features of human
CF pathology are early damage to the pancreas, which initiates when pancreatic acini become functional in utero,
intestinal obstruction, and persistent lung inflammation
associated with infection that causes tissue damage and
fibrosis (Reviewed in2). One of the impediments in advancing the understanding of disease mechanisms is the
limited ability of most CF animal models to recapitulate
some aspects of the disease phenotype observed in humans (reviewed in3,4). Of particular importance is the etiology of early lung pathology, which is likely triggered by
functional inactivation of CFTR protein early in life.5
There are over 2000 predicted CFTR mutations that are
divided into six classes, depending on how they affect the
protein.6 The F508del mutation is the most frequent in
human patients in the United States, followed by G542X.
The F508del is identified in 84.7% of patients on at least
one allele, whereas the G542X is present at a frequency
of 4.6%.7 The F508del mutation is characterized by loss of
a phenylalanine residue at the position 508 (F508) of the
CFTR protein and is classified as a Class II alteration since
it causes defective processing/trafficking. F508del protein
is misfolded and retained in the endoplasmic reticulum
(ER) where it is further degraded by proteolytic cleavage.8
As the most common human CFTR mutation, the F508del
CF sheep was considered necessary as a valid ovine model
for evaluating lung disease progression in sheep and the
development of future therapeutic treatments. Though
substantial progress has been made with small molecule approaches to correct this mutant phenotype9,10 (reviewed in11), some patients are poorly responsive to these
treatments.
Although effective treatments are now available for
CF patients with at least one F508del allele, there is still a
great need for therapeutics that target CFTR nonsense mutations (e.g., G542X). These nonsense mutations are Class
I alterations, which lack full length of the CFTR protein
production and are often targets for nonsense-mediated
decay (NMD) of RNA. Nearly 10% of CF patients carry
Class I mutations, the most common being G542X, a G to
T substitution in the first nucleotide of the glycine codon
(GGA) at position 542 of the protein. This mutation produces a premature termination codon (PTC), which triggers the surveillance pathway and causes mRNA NMD,
leading to the lack of CFTR protein production.12
To the best of our knowledge, no large animal model
carrying the G542X mutation has been produced to
study in-depth the nonsense mutations that affect CF patients. Therefore, to better elucidate the pathophysiologic

effects of the F508del and G542X mutations, we produced CFTRF508del/F508del and CFTRG542X/G542X sheep using
CRISPR/Cas9 ribonucleoprotein (RNP) along with donor
single-stranded oligonucleotide (ssODN) to introduce either the F508del or G542X mutations in the CFTR gene
of sheep fetal fibroblasts followed by somatic cell nuclear
transfer (SCNT). Here, our goal was to investigate whether
F508del and G542X CF sheep models exhibit the same
phenotypes as were observed in the CFTR−/− sheep we
generated previously.5 Also it was important to establish
the presence of residual CFTR channel activity in F508del
CF sheep. We evaluated the effect of CFTR correctors
(VX-661 (Tezacaftor),13 VX-809 (Lumacaftor),14 and VX-
445 (Elexacaftor)15) and potentiator (VX-770 (Ivacaftor)16)
on the restoration of the CFTR channel function in the
F508del CF sheep tracheal epithelial (STE) cells by electrophysiology. We also measured the impact of aminoglycoside antibiotics (gentamicin (G418))17 and the NMD
inhibitor (SMG1-i (2-chloro-N,N-diethyl-5-((4-(2-(4-(3-m
ethylureido)phenyl)pyridin-4-yl)pyrimidin-2-yl)amino)
benzenesulfonamide))18 in G542X CF STE cells. These
novel F508del and G542X CF sheep models could become
a critical platform for studying the effects of CFTR mutations during fetal development, the mechanisms of onset
of lung inflammation, and also provide support for new
therapeutic strategies including prenatal therapy toward a
genetic cure of the disease.
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METHODS
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Animals

Domestic Romney sheep (Ovis aries) were used in this
study for isolation of sheep fetal fibroblasts (SFFs), and
Suffolk and Rambouillet ewes were used as recipients
for embryo transfers. All animal studies were approved
and monitored by the Institutional Animal Care and Use
Committee (IACUC) at Utah State University (IACUC protocol #10089) and conformed to the National Institute of
Health guidelines. CFTRF508del/F508del and CFTRG542X/G542X
cloned lambs were generated by SCNT using genetically
modified SFFs as nucleus donor cells.

2.2
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Sheep fetal fibroblasts

Sheep fetal fibroblasts were isolated from male day 45
Romney fetus as previously described and cultured in
Dulbecco's modified Eagle's medium ((DMEM) high glucose; HyClone) supplemented with 15% fetal bovine serum
(FBS; HyClone) and 100 U/mL penicillin–streptomycin (Life
Technologies) at 38.5℃ in an atmosphere of 5% CO2 in air.19

VIOTTI PERISSE et al.

2.3 | Design of guide RNAs/Cas9 and
single-strand oligonucleotides
Based on the sequence results for exons 11 and 12 of the
ovine CFTR gene, we designed gRNAs targeting the regions flanking the phenylalanine (F508) site in exon
11 and the Glycine (G542) site in exon 12 using the
Benchling software (https://bench
ling.com/academic)
(Figure 1). The gRNA_1 targets the F508 site with the
intended “CTT” deletion located within the first and
third nucleotide at 3’ end. The gRNA_2 targets the G542
DNA locus with the target nucleotide (Guanine) located
within five positions upstream to the CRISPR/Cas9
double-strand break site. The gRNAs were synthesized
by Synthego with chemical modifications (2’-O-methyl
3’-phosphorothioate modifications in the first and last
three nucleotides). The TrueCut™ Cas9 V2 protein was
purchased from Thermo Fisher Scientific. To introduce
the point mutations, we also designed ssODNs carrying
either the G542X or F508del mutations as gene-editing
donor oligos with 50 bp homologous arms flanking the
mutation sites. The ssODN_1 (5’-T*G*CTCTCAGTATTC
CTGGATCATGCCTGGAACCATTAAAGATAACATCA
TTGGTGTTTCCTATGATGAATATAGATATAGGAGTG
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TCATCAAAGCATG*C*C-3’) carried the F508del mutation (a deletion of three consecutive nucleotides, “CTT”)
and the ssODN_2 (5’-
T*T*TGATAATAGGACATCTCC
AAGTTTTCAGAGAAAGACAACATAGTTCTTTGAGA
AGGTGGAATCACATTGAGTGGAGGTCAGCGAGCA
AGAATTTCTT*T*A-3’) contained the G542X mutation
(a “G” nucleotide was replaced with a “T” (bold) leading
to the generation of a stop codon, “TGA”). Both ssODNs
were synthesized by Integrated DNA Technologies (IDT)
containing two phosphorothioate modifications (*) at
both 5’ and 3’ ends.

2.4 | Transfection and mutation
efficiency detection
Nucleofection was performed using an Amaxa
Nucleofector System (Program EH-100, Lonza). Prior
to transfection, 3 µl of 100 µM gRNA was incubated
with 2 µl of 5 µg/µl Cas9 protein for 10 min at room
temperature to form a ribonucleoprotein (RNP) complex. The RNP was then incubated with 2 µl of 200 µM
ssODN for 5 min and transfected into 2 × 105 SFFs, in
Passage 3, in a 100 µl nucleocuvette system. Two days

F I G U R E 1 Generation of CFTRF508del/F508del and CFTRG542X/G542X sheep fetal fibroblast cells and lambs. (A) Schematic diagram of
CRISPR/Cas9 target sites in exon 11 and 12 for introduction of the F508del and G542X mutations using the ssODN_1 and 2, respectively.
The blue arrows represent the primers used to amplify the exon 11 and 12. (B) Representative sequence analysis for cell colonies and lambs
containing F508del, similar to the CF patients, the “CTT” nucleotides are deleted between the codons ATC and TTT. Sequencing results
indicate that four isolated cell colonies and two cloned lambs contained homozygous F508del mutations. (C) Representative sequence
analysis for cell colonies and lambs containing G542X mutation. Similar to the G542X CF patients, Glycine-encoded codon “GGA” is
mutated with a single nucleotide replacement, “G” to “T,” leading to the generation of stop codon, “TGA.” Sequencing results demonstrate
that all nine SFF cell colonies and three cloned fetus/lambs present the same homozygous G542X mutation. The arrow represents the point
mutation site and the codon sequences are framed
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post-
transfection, cells were harvested for genomic
DNA isolation using the DNeasy Blood & Tissue kit
(Cat. 69504, Qiagen) following the manufacturer's
protocol. Each of the targeted genomic loci was PCR
amplified by Phusion High-
fidelity DNA polymerase
(Thermo Fisher Scientific) using the genomic DNA
isolated from transfected SFFs as templates and the
primers (F: 5’-TGAACTCAGCACCCCATCTCTG-3’; R:
5’-TGCAGGCTTCTTATAGCAGGGG-3’) for F508 locus,
and the primers (F: 5’-GCTGAGATGT GGTGTTCACA-3’;
R: 5’-GCATCTTCTCTTCC CTGTGC-3’) for G542 locus.
Both PCR products were analyzed by Sanger sequencing
before cell colony isolation.

2.8

2.5 | Isolation of F508del and G542X
cell colonies

2.9

Three days after gRNA/Cas9/ssODN transfection, cells
were subjected to single-cell colony isolation by serial dilution in 96-well plates. After 7 days culture in a 96-well
plate, each single cell-derived colony was allowed to grow
to near confluence and then transferred into individual
wells of 24-well plates for 3 more days of culture. Upon
reaching confluence, three quarters of the cells were
cryopreserved, and one quarter used for DNA extraction.
PCR and Sanger sequencing were then performed to identify wild-type (WT), knock-out (KO), and knock-in (KI)
colonies.

2.6
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Somatic cell nuclear transfer

Sheep SCNT was performed as described by Yang et al.
for goats20 with the minor alteration that the synthetic
oviductal fluid (SOF) embryo culture medium was used
instead of G1. CFTRF508del/F508del and CFTRG542X/G542X fetal
fibroblast cells were grown to 80%–90% confluence and
used as nuclear donor cells for SCNT after 24 h of serum
starvation (in 0.5% FBS-containing DMEM medium). The
reconstructed embryos were cultured in SOF medium for
10–12 h and then transferred into estrus synchronized recipients as described elsewhere.19,21

2.7 | Identification of CFTRF508del/F508del
and CFTRG542X/G542X fetuses/lambs
Genomic DNA was extracted from muscle samples collected during the necropsy. Using the set of primers described above, PCR and Sanger sequencing analysis were
used for confirmation of the mutations present in the
lambs.

|

Off-target analysis

We conducted a BLAST search on the sheep nucleotide
sequence database with two gRNA sequences as the queries to find the genomic sequences with the highest homology using Crispor online software (Version 4.97).
We selected potential off-target sites with the highest sequence homology (scores) to each seed sequence. Specific
PCR primers were designed to amplify DNA fragments of
approximately 500 bp spanning each OT locus. We used
PCR and Sanger sequencing for off-target analysis of the
genomic DNA isolated from cloned CFTRF508del/F508del and
CFTRG542X/G542X sheep.

|

Histopathologic analysis

Necropsy was performed on all lambs that either died or
were euthanized within 24 h of birth. The following tissue
samples were collected and fixed in 10% neutral buffered
formalin for histology: trachea, lung, thyroid glands, adrenal glands, abomasum, intestinal tract, pancreas, liver,
kidney, urinary bladder, spleen, heart, testis, and vas
deferens, or the area where the vas deferens is expected.
Formalin-fixed tissue sections were processed and embedded in paraffin according to the routine histologic
techniques. Sections, 5-µm thick, were stained with hematoxylin and eosin (H&E), based on standard methods,
and examined by light microscopy.

2.10 | Tracheal cell isolation, primary
culture, and electrophysiological analysis
G542X and F508del CF STE cells were prepared as in a
previous study.5 Briefly, tracheal segments were digested
by injecting the subepithelial space with a collagenase
solution (type I, 1 mg/mL; Worthington) and incubated
at 37℃ for 1 h. After digestion, the epithelial sheets on
the luminal surface were collected by scraping, using a
plastic coverslip. These sheets were washed and then further digested with Accutase into single cells and small
clumps. The cells were then seeded onto permeable supports (Costar 3801) with bronchial epithelial growth medium (BEGM; Lonza) in both upper and lower chambers.
Once the cells were post-confluent for 3 days, the culture medium was switched to PneumaCult-ALI medium
(STEMCELL Technologies) in the lower chamber only
for air–liquid interface (ALI) culture. After 6 weeks, the
ALI cultures were differentiated into polarized epithelia,
which were used for the measurements of transepithelial
electrophysiology. The filter inserts were placed in Ussing
chambers and bathed on both sides with Krebs-Ringer

VIOTTI PERISSE et al.

TABLE 1
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Developmental rates following the SCNT using CFTRF508del/F508del and CFTRG542X/G542X fibroblasts as donor cells
No of embryos
transferred

Pregnancy rate
(%)

Term rate (%)

No lambs
born alive/
total (%)

KI colonies (Genotype)

Targeted exon

Fd78 (F508del/F508del)

Exon 11

47

1/3 (33.3)

1/3 (33.3)

1/1 (100)

Fd92 (F508del/F508del)

Exon 11

27

1/2 (50.0)

1/2 (50.0)

1/1 (100)

a

Gx12 (G542X/G542X)

Exon 12

48

1/3 (33.3)

0/3 (0)

NA

Gx44 (G542X/G542X)

Exon 12

42

2/3 (66.6)

2/3 (66.6)

1/2(50)b

164

5/11 (45.4)

4/11 (36.3)

3/4 (75)

Total
a

Fetus collected for isolation of G542X sheep fetus fibroblasts.

b

The second lamb died about 24 h prior to birth.

bicarbonate solution bubbled with 95% O2/5% CO2
and maintained at 37℃, as described previously.22,23
Transepithelial voltage was measured and clamped to 0
to measure the short-circuit current. The epithelium was
periodically voltage-
clamped to non-
0 values to measure transepithelial resistance. In addition, ciliary beating was observed and recorded in both STE cultures (see,
Supporting Information Videos).

2.11 | Effect of CFTR correctors/
potentiator on F508del and G542X CF
STE cells
F508del STE cell cultures were pretreated with the correctors VX-809, VX-661, or VX-445 at 3.3 μM for 24 h. For the
triple combination (as in Trikafta®) VX-661 and VX-445 at
3.3 μM were used together for 24 h. At the indicated times,
amiloride (100 μM, apical), forskolin (10 μM, basolateral),
VX-
770 potentiator (1 μM, apical & basolateral), genistein (30 μM, apical & basolateral), and CFTR inhibitor
GlyH-101 (20 μM, apical) were added for acute treatment.
G542X CF STE cells were pretreated with the inhibitor of
NMD SMG1-i (1 μM)18 plus G418 (50 μM) for 24 h with or
without VX-661 (3.3 μM), followed by acute treatment as
described above.

3
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R E S U LTS

3.1 | Generation of CFTR
and CFTRG542X/G542X sheep fetal fibroblast
colonies using CRISPR/Cas9 RNP and
ssODN
F508del/F508del

Fetal fibroblasts from domestic sheep (O. aries) were used
in this study, since they are the preferred cell type for cloning.24 The cells were isolated as previously described.21
We designed specific PCR primers according to the sheep
CFTR genome sequence (GenBank, NC_019461.2) to

amplify exon 11 (F: TGAACTCAGCACCCCATCTCTG,
R: TGCAGGCTTCTTATAGCAGGGG, 624 bp) and
exon 12 (F: GCTGAGATGTGGTGTTCACA, R: GCATC
TTCTCTTCCCTGTGC, 560 bp) and parts of the flanking
intron sequences. We designed guide RNA/Cas9 (gRNA/
Cas9) targeting sites that were close to the F508 and G542
(gRNA_1: 5’-ATTAAAGATAACATCATCTT-3’ and
gRNA_2: 5’-AACATAGTTCTTGGAGAAGG-3, for exon
11 and 12, respectively), of the CFTR gene. The F508del
and G542X mutations were introduced into the corresponding sites of ssODNs in order to induce mutations
in SFFs via CRISPR-mediated homology-directed repair
(HDR) (Figure 1A). SFFs were transfected with gRNA/
Cas9 RNP and ssODNs using an electroporation-based
method. After limiting dilution of the transfected cells,
we obtained 56 single cell-derived colonies in the F508del
group and 62 colonies in the G542X group. The PCR and
Sanger sequencing results demonstrated that mutations,
including insertions/deletions (indels) mutations and KIs,
were introduced in 53/56 (94.6%) of colonies targeting the
F508del site, and four of them (7.1%) contained homozygous F508del mutations (Figure 1B). Whereas a total of
mutations were found in 61/62 (98.4%) of colonies in the
G542 site, and nine of them (14.5%) contained homozygous G542X mutations (Figure 1C). Four colonies, two
from each mutation, were subsequently used for the generation of CFTRF508del/F508del and CFTRG542X/G542X lambs.

3.2 | Generation of CFTRF508del/F508del and
CFTRG542X/G542X sheep by SCNT
Four SFFs colonies (two with CFTRF508del/F508del and
two with CFTRG542X/G542X mutations) were used as
donor cells for SCNT. In total, 164 cloned embryos were
transferred into 11 estrus-synchronized recipients. Five
pregnancies were initially established, two from the
F508del and three from the G542X cells (Table 1). One
of the G542X pregnancies was sacrificed around day 40
of gestation and the fetus was used for SFFsG542X/G542X

Obstruction, Meconium
ileus 2/2 (100%)

Obstruction, Meconium
ileus 15/15 (100%)

CFTR G542X/G542X
(n = 2)

CFTR−/− (n = 15)b

Reference CFTR−/− CF sheep data from Fan et al. (2018).

a

Obstruction, Meconium
ileus 2/2 (100%)

CFTR
F508del/F508del
(n = 2)

Small intestine

Vas deferens
Aplasia or atrophy,
bilateral
cryptorchidism 2/2
(100%)

Gallbladder
Hypoplasia
1/2 (50%)

Hypoplasia
12/15
(80%)

Aplasia or atrophy
12/12 (100%)

Portal ductular reaction,
Hypoplasia
Aplasia or atrophy,
mild (1) to severe (1),
2/2 (100%)
unilateral
with mild fibrosis
cryptorchidism 2/2
Intrahepatic cholestasis,
(100%)
moderate (1) to severe (1)
2/2 (100%)

Portal ductular reaction,
severe, with mild fibrosis
Intrahepatic cholestasis,
mild (1) to severe (2)
2/2 (100%)

Liver

Hypoplasia or aplasia 11/15
Portal ductular reaction
(73.3%) Fibrosis 6/15 (40%)
and fibrosis, mild to
severe 11/14 (78.6%),
intrahepatic cholestasis,
mild to severe 12/14
(85.7%)

Hypoplasia, mild (1)
and severe (1) Acini/
duct dilation, minimal
inflammation 2/2 (100%)

Hypoplasia, mild (1) to severe
(1)
Acini/duct dilation, minimal
inflammation 2/2 (100%)

Pancreas

Pathologic findings in CFTRF508del/F508del and CFTRG542X/G542X lambs

No lesions

No lesions

No lesions

Lung

Hydronephrosis
13/15 (86.6%)

Hydronephrosis
2/2 (100%)

Hydronephrosis
2/2 (100%)

Kidney

|

TABLE 2
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cell rederivation. The remaining pregnancies (n = 4)
were allowed to go to term. They resulted in three live
offspring and one stillborn lamb. Abdominal ultrasonography confirmed the presence of intestinal obstruction
(meconium ileus (MI)) in all F508del and G542X CF offspring. Thus, they were considered not viable due to the
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7

MI and were euthanized within a few hours after birth.
The sequencing results indicated that all cloned fetuses/
lambs carried the same mutations (either F508del or
G542X) as those of the donor cells they were derived
from (Figure 1B,C). All lambs were submitted for necropsy and tissue collection.

8
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F I G U R E 2 Wild-type (A, D, G, J, and M), F508del (B, E, H, K, and N), and G542X (C, F, I, L, and O) newborn lamb intestinal tract.
(A) Normal intestinal tract in a wild-type lamb. Note the even intestinal diameter of the small intestine (arrow) and colon (arrowhead). (B)
Meconium ileus in an F508del lamb (C) Meconium ileus in a G542X lamb. Note the smaller diameter of the aboral small intestine (arrow),
and of the colon (arrowhead). (D) Normal small intestine in a wild-type lamb. (E) Small intestine filled with meconium in an F508del
lamb. (F) Small intestine filled with meconium in a G542X lamb. (G) Higher magnification of the small intestine in a wild-type lamb.
(H) Higher magnification of the small intestine filled with meconium in an F508del lamb. (I) Higher magnification of the small intestine
filled with meconium in a G542X lamb. (J) Normal colon in a wild-type lamb. (K) Colon filled with mucus in an F508del lamb. (L) Colon
filled with mucus in a G542X lamb. (M) Higher magnification of the colon in a wild-type lamb. (N) Higher magnification of the colon in
an F508del lamb. (O) Higher magnification of the colon in a G542X lamb. Note the large amount of luminal mucus (arrow) and the goblet
cells distended with mucus (arrowhead). Hematoxylin and eosin stain (D–O). 40X (D–F and J–L); bar = 500 μm. 200X (G–I and M–O);
bar = 100 μm

3.3 | Gross and histologic
characterization of the
CFTRF508del/F508del and CFTRG542X/G542X sheep
The histopathologic findings of all CFTRF508del/F508del and
CFTRG542X/G542X sheep are detailed below and summarized in Table 2.

3.3.1

|

Intestinal phenotype

Similar to the CFTR-
null sheep,5 100% of the
F508del/F508del
CFTR
(n = 2) and CFTRG542X/G542X (n = 2)
newborn lambs exhibited intestinal obstruction (MI),
(Figure 2; Table 2), a phenotype seen only in ~15% of
human CF babies. An abrupt demarcation between

F I G U R E 3 Wild-type (A, D, and G), F508del (B, E, and H), and G542X (C, F, and I) newborn lamb pancreas. (A) Normal pancreas
in a wild-type lamb (arrow). (B) Pancreas in an F508del lamb (arrow). (C) Pancreas in a G542X lamb (arrow). (D) Pancreas of a wild-type
lamb. (E) Pancreatic acinar atrophy (arrow) and dilatation of acini and ducts (arrowhead) in an F508del lamb. (F) Pancreatic acinar atrophy
(arrow) and dilatation of acini and ducts (arrowhead) in a G542X lamb. (G) Higher magnification of the pancreas in a wild-type lamb. (H)
Higher magnification of the pancreatic acinar atrophy and dilatation of acini (arrow) in an F508del lamb. (I) Higher magnification of the
pancreatic acinar atrophy and dilatation of acini (arrow) and ducts (arrowhead) in a G542X lamb. Hematoxylin and eosin stain (D–I). 40X
(D–F); bar = 500 μm. 200X (G–I); bar = 100 μm

VIOTTI PERISSE et al.
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F I G U R E 4 Wild-type (A, D, and G), F508del (B, E, and H), and G542X (C, F, and I) newborn lamb liver. (A) Normal liver wild-type
lamb. Note the well-developed gallbladder. (B) Gallbladder hypoplasia in an F508del lamb. (C) Gallbladder hypoplasia in a G542X lamb.
Note the small gallbladder (arrow). (D) Normal liver in a wild-type lamb. (E) Biliary fibrosis in an F508del lamb. (F) Biliary fibrosis in a
G542X lamb. (G) Higher magnification of the liver in a wild-type lamb. (H) Higher magnification of the liver with biliary fibrosis in an
F508del lamb. (I) Higher magnification of the liver with biliary fibrosis in a G542X lamb. Note the intrahepatic cholestasis (arrow) in
image H and I. Hematoxylin and eosin stain (D–I). 40X (D–F); bar = 500 μm. 200X (G–I); bar = 100 μm

a distended oral intestine and small-
diameter aboral
small intestine and colon (Figure 2B,C) was present in
three out of four lambs. The change in intestinal diameter at the level of the obstruction was less abrupt and
extended over an approximately 3 cm long segment in
one of F508del lamb. Obstruction was consistently seen
in the mid jejunum. The intestine oral to the obstruction
point was markedly dilated (ranging from 10 to 40 mm
in diameter) and contained large amount of meconium
(Figure 2E,F,H,I). The intestine and colon aboral to
the obstruction site had a small diameter (4–
8 mm)
and contained thick mucoid content. Microscopic examination revealed a mucus filled colonic lumen with
dilated mucosal glands (Figure 2 K,L,N,O). The gross
and microscopic lesions were identical to the ones seen
in CFTR−/− lambs5 and associated with CF disease in
humans.

3.3.2

|

Pancreas

The pancreas of all animals was grossly normal in size
(Figure 3B,C). However, in all CF lambs, microscopic
examination showed variably sized areas of atrophic exocrine pancreas admixed with normal pancreatic tissue
(Figure 3E). The atrophic exocrine pancreatic tissue was
composed of small acini with sometimes a dilated lumen
separated by increased amount of stroma arising from either collapsing of the preexisting stroma or mild fibrosis
(Figure 3E,F,H,I). Several acini or ducts with a dilated
lumen contained few neutrophils and macrophages. In
addition, a few acini and/or ducts had a markedly dilated
lumen that contained lightly basophilic flocculent material that stained with alcian blue and periodic acid-Schiff
stain supporting it is likely mucus. These early pancreatic
lesions are similar to those reported in humans with CF
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disease25 and were also seen in a few CFTR−/− lambs as
described by.5

3.3.3

|

Liver and gallbladder

The liver of all lambs was grossly normal but the gallbladder in three out of four lambs was approximately one
quarter of the expected size (Figure 4B,C). In the lamb
with a gallbladder of normal size, the cystic duct was
tortuous and the gallbladder was found approximately
2 cm more ventral than normal. Microscopic examination revealed moderate to severe bile duct proliferation
(ductular reaction) and mild fibrosis in most portal tracts
diffusely (biliary fibrosis) in three out of four animals
(Figure 4E,F,H,I). Similar lesions but mild were present
in the stillborn lamb. Intrahepatic cholestasis was severe
in three lambs, and mild in one lamb (Figure 4H,I). These
liver lesions were also seen in CFTR−/− sheep5 and are
similar to the phenotype of early onset CF liver disease
reported in humans.26,27

3.3.4

|

Epididymis and vas deferens

None of the lambs had a grossly visible or microscopically
detectable vas deferens. Epididymis was present in all
animals. However, bilateral cryptorchidism, was present
in both F508del CF lambs, and unilateral cryptorchidism
was present in the G542X CF lambs (one right and one
left cryptorchid). Cryptorchidism, an absence of at least
one testis from the scrotum, is not a CF-associated lesion and was not previously described in our CFTR-null
sheep,5 also it may occur due to various factors, such as
birth weight, absence of appendix testis, as well as maternal and environmental factors that disrupt hormones and
physical changes.28

3.3.5

|

Lungs

The lungs of the F508del and G542X CF lambs were
grossly and microscopically unremarkable.

3.3.6

|

Kidney

Hydronephrosis, a common pathology in cloned sheep29,30
and cattle31,32 associated with SCNT, was evident in all
four CF lambs.

3.3.7

|

Other organs

One lamb (G542X CF) had a moderately rounded heart
due to right ventricular dilation, whereas all other animals had no heart lesions. Three lambs had a small (±
20 mL) to moderate (± 100 mL) amount of translucent
watery fluid in the abdominal cavity, while the stillborn
lamb had the thoracic and abdominal cavities filled with
dark red watery fluid. These lesions were most likely associated with SCNT.33 No microscopic lesions were detected
in the other evaluated tissues including thyroid gland, adrenal glands, trachea, thymus, spleen, umbilicus, skeletal
muscle, forestomach, urinary bladder, and brain obtained
from either F508del or G542X CF lambs.

3.4 | Functional
rescue of mutant ovCFTR using
hCFTR therapeutic compounds
In order to evaluate whether the Vertex compounds, which
achieve partial functional rescue of mutations in human
CFTR (hCFTR), are also effective on equivalent mutations
in ovine CFTR (ovCFTR), we treated STE cells with the
relevant reagents and monitored CFTR channel activity
in Ussing chambers. Treatment with VX-661,13 VX-809,14
and VX-445,15 all three of which promote maturation/correct folding of F508del hCFTR, increased the function of
F508del ovCFTR in STE cells (Figure 5A). Following activation of F508del ovCFTR with the VX-770 potentiator
of hCFTR,16 the increased short-circuit current caused by
the corrector was VX-445 > VX-661 > VX-809 (Figure 5A).
The most potent activation was observed with the triple
combination of simultaneous treatment with VX-445 and
VX-661, followed by VX-770 (Figure S1). In the G542X
STE cells, the function of ovCFTR G542X was moderately
restored by SMG1-i18 and G41817 treatments (Figure 5B).
Furthermore, exposure to G418 with VX-661 alone did not
improve the CFTR function (not shown).

3.5 | Evaluation of potential
introduction of mutations in off-target
sites by CRISPR/Cas9
To examine whether unintended off-targeting (OT) events
occurred in CFTRF508del/F508del or CFTRG542X/G542X sheep, we
conducted a blast search of the sheep nucleotide sequence
database with CFTR targeting sequences as the queries to
find the genomic sequences with the highest homologies.
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from two F508del and three G542X cloned sheep were
used as the templates for PCR amplification. Sequencing
results verified that none of the animals had mutations in
the analyzed potential OT sites (Figure S2).

4

F I G U R E 5 Representative traces of short-circuit current in
CFTR F508del and G542X sheep tracheal epithelial cell cultures.
Primary cultures of sheep tracheal epithelial cells were seeded onto
permeable filter supports and maintained at the ALI for 6 weeks.
At the time of measurement, the filter inserts were placed in Ussing
chambers and bathed on both sides with Krebs-Ringer bicarbonate
solution bubbled with 95% O2/5% CO2 and maintained at 37℃.
(A) Effect of CFTR correctors on F508del cells. Cultures were
pretreated with VX-809, VX-661, or VX-445 at 3.3 μM for 24 h. At
the indicated times, amiloride (Amil, 100 μM, apical), forskolin
(For, 10 μM, basolateral), VX-770 (1 μM, apical & basolateral),
genistein (Gen, 30 μM, apical & basolateral), and GlyH-101 (20 μM,
apical) were added for acute treatment. (B) Effect of G418 and
SMG1-i on G542 cells. Cells were pretreated with SMG1-i (1 μM)
plus G418 (50 μM) for 24 h with or without VX-661 (3.3 μM),
followed by acute treatment as described above

We chose 10 potential OT sites related to the gRNA_1 and
11 OT sites to the gRNA_2 in the sheep genome with the
highest sequence homology (scores >1) for the OT analysis (Table S1). Specific PCR primers were designed to amplify DNA fragments ranging from 300 to 800 bp spanning
each potential OT locus (Table S2). Genomic DNA isolated

|

DISC USSION

One impediment to advancing the understanding of CF disease mechanisms is the limited ability of most CF animal
models to recapitulate some aspects of humans’ disease
phenotype (reviewed in34). Also, the CFTR-null models
do not represent the same molecular mechanisms seen in
patients with the most common mutations, F508del and
G542X, as the random disruption of the gene may lead
to unpredictable effects on protein synthesis. Currently,
a few F508del and G542X CF animal models have been
established, including pig,35 rat,36,37 and mouse38 for the
F508del mutation, and mouse39 and rat40 for the G542X
mutation. The F508del mutants have similar abnormalities as seen in their respective CFTR-null models of the
same species, except with less severe damage in some organs due to residual CFTR function35,36 (reviewed in41).
The availability of sheep models of the F508del and G542X
mutations provides an extremely valuable resource, not
only to reveal critical events in the early pathology of CF
disease, which are not accessible in humans, but also to
evaluate new therapeutic approaches. Similar to our observations on the efficacy of the Vertex therapeutics to
restore the function of ovine F508del CFTR protein, primary nasal cultures of F508del rats demonstrated that the
combination of VX-809 and VX-770, human therapeutics,
restored CFTR function, and improved the Cl− anion
transport up to 37%.36 Thus these therapeutics may be effective in multiple species as the molecular mechanism of
the CFTR synthesis seems to be similar. Of note, ongoing efforts to optimize CFTR correctors, which although
they correct the folding process do not restore the reduced
open state probability of the F508del CFTR channel,42 may
also benefit from additional animal model systems for in
vivo studies. Nonetheless, even with these most promising postnatal treatments, they cannot fully correct all the
deficits arising from the absence of appropriate CFTR levels during fetal development. For this reason, the F508del
CF sheep models may also be an excellent candidate to
test not only postnatal but also prenatal therapeutic approaches. Sheep, like humans, frequently have one to two
offspring, which provides an advantage for prenatal treatment. CF pig models, on the other hand, require a minimum of four offsprings to maintain the pregnancy,43 and
normally have 6–10 offspring per pregnancy.
G542X CF mice and rats were generated recently39,40
and exhibit a similar phenotype to their CFTR-
null
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models with no residual CFTR functionality. However, organoids isolated from the intestine of G542X CF mice and
epithelial cells isolated from the trachea of G542X CF rats
indicated that CFTR protein synthesis could be rescued
by G418 antibiotic treatment, thus, partially restoring the
CFTR channel. Also, McHugh et al. observed that the intestinal organoids from the same G542X CF mouse, when
treated with PTC124, showed no enhancement of CFTR
gene transcription.39 More recently, McHugh et al. tested
the efficacy of a combination of read-through agents and
NMD inhibitors to restore the CFTR function in primary
airway epithelial (PAE) cells from a G542X CF mouse
model. Their analysis strongly indicates that the SMG1-i
and G418 act in synergy to restore the CFTR channel in
PAE cell cultures.44 Furthermore, several studies45–48 have
demonstrated that drugs like G418 and PTC124 enable ribosomes to read through nonsense mutation sites of PTC
by inserting a near-cognate aminoacyl tRNA that inserts a
range of alternative amino acids to allow translation of the
full-length protein; thus, preventing early PTC. However,
these compounds cause side effects or provide no significant enhancement, that is, gentamicin is nephro and ototoxic, whereas PTC124 has little impact on clinical disease
in CF patients in Phase 3 clinical trials. Therefore, currently, there are no adequate and safe therapies available
to recover the production of the CFTR gene for nonsense
mutations.12,39 Again, the G542X sheep model may serve
as not only an excellent candidate for the discovery of new
corrective drugs but also prenatal therapeutic approaches.
Among all etiologies associated with CF, one of particular importance is the early lung pathology, which is
likely triggered by functional inactivation of the CFTR
protein early in life. Current models of human lung development heavily rely on seminal work in the sheep lung,
carried out many decades ago (reviewed in49).50 Also, the
developmental time course of CFTR gene expression in
the sheep lung appears similar to limited observations in
humans.51–54 Hence, it is evident that the availability of
CF sheep models could be a valuable asset to reveal key
events in the human CF lung, which are not accessible for
study in vivo in humans.55 Similar to human CF patients,
newborn CF sheep do not exhibit any histological lung
lesions. However, further molecular characterization of
the lung tissue derived from these animals could provide
novel insights into CF-associated deficits occurring prior
to observations of clinical lesions. Due to meconium ileus,
our current models only survive 24–48 h after birth, and
therefore, the short life span prevents further studies. To
overcome this limitation, we intend to genetically correct
the intestinal phenotype by expressing a transgene under
regulation of an intestinal cell-specific promoter, similarly
to what was previously accomplished in mice, ferrets, and
pigs.56–58 On these aspects, CF sheep models carrying the
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most common mutations (F508del and G542X) seem necessary in order to advance the research on the CF disease.
Here, we generated two models of human CF mutations in sheep that develop pathologies similar to what
is seen in human patients. Analogous to the F508del CF
rat and G542X CF rat and mouse, our F508del and G542X
CF sheep cells are very responsive to the CFTR correctors (VX-661, VX-809, and VX-445) and potentiator (VX-
770) in F508del STE cells, as well as for SMG1-i and G418
with and without corrector (VX-661) in G542X STE cells,
respectively. As was shown earlier, the ovCFTR channel
is more active than the human channel and the F508del
mutation in sheep has a reduced impact in vitro on channel gating when compared to hCFTR protein.59 Thus, our
F508del CF sheep model may contribute substantially to
the discovery of new therapeutics. G542X CF models, on
the other hand, remain poorly understood as only one
mouse model has recently been generated, and does not
recapitulate all aspects of CF in humans as reviewed in.39
Our G542X CF model will likely provide a robust platform
to study in-depth the effects of nonsense mutations in the
CFTR gene and provide an opportunity to enhance the in
vivo development of therapeutics that overcome the PTC.
Moreover, with the rapid advancement of CRISPR/Cas9
technologies as molecular tools, both CF models may
provide excellent platforms to observe the correction of
the CFTR gene through gene editing and gene therapy
approaches.
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